Intermittent Chemotherapy and Erlotinib for Nonsmokers or Light Smokers with Advanced Adenocarcinoma of the Lung: A Phase II Clinical Trial

Figure 3

Progression-free survival in relation to the status of EGFR gene activating mutations.